---
title: "Asston Pharmaceuticals Ltd (544445) — Share Price, Financials & Analysis"
symbol: "544445"
company: "Asston Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/544445"
isin: "INE0SJX01015"
nse_symbol: "ASSTONPHARMACEUTICALSLTD"
bse_code: "544445"
sector: "Capital Goods"
industry: "Other Electrical Equipment"
market_cap_cr: 116.9
generated_at: "2026-09-13T18:47:54.526Z"
---

# Asston Pharmaceuticals Ltd (544445)

Canonical page: https://tapetide.com/stocks/544445

## Company

- **NSE Symbol:** ASSTONPHARMACEUTICALSLTD
- **BSE Code:** 544445
- **ISIN:** INE0SJX01015
- **Sector:** Capital Goods
- **Industry:** Other Electrical Equipment
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-07-16
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** asstonpharmaceuticals.com

## About

Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:34:47.049719Z.

- **Market Cap:** ₹116.9 Cr
- **Classification:** SME
- **P/E (reported):** 30.2
- **Book Value:** ₹60.96
- **Price to Book:** 1.76
- **Dividend Yield:** 0%
- **ROE:** 34.91%
- **ROCE:** 44.34%
- **Debt to Equity:** 0.13
- **Revenue (yearly):** ₹25.47 Cr
- **Net Income:** ₹3.97 Cr
- **EBITDA:** ₹-0.56 Cr
- **52-Week High:** ₹126.1
- **52-Week Low:** ₹60
- **RSI (14):** 59.15

## Tapetide Score

- **Score:** 48 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 39.4 (of 4473 scored stocks)
- **Confidence:** 86%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 70.49 | 9% |
| growth | 39.73 | 9% |
| momentum | 92.48 | 12% |
| ownership | 33.7 | 24% |
| quality | 54.57 | 22% |
| valuation | 34.68 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.6.12 Cr.
- Company has high debtors of 524 days.
- Working capital days have increased from 259 days to 434 days

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 99.24% | 90.63% | -100.76% |
| ebitda margin growth | -107.55% | -110.01% | -131.11% |
| net income growth | 1.79% | 54% | — |
| revenue growth | -0.51% | 57% | 19.16% |
| roce | 32.28% | -18.82% | 40.77% |
| roe | 64.05% | 36.47% | -34.39% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 15.97 | 9.07 | 15.42 | 10.05 |
| Expenses | 13.71 | 5.89 | 13.19 | 12.85 |
| Operating Profit | 2.26 | 3.18 | 2.23 | -2.8 |
| OPM % | 14.15 | 35.06 | 14.46 | -27.86 |
| Other Income | 0.64 | -0.07 | -1.86 | 4.63 |
| Interest | 0.42 | 0.53 | 0.28 | 0.36 |
| Depreciation | 0.02 | 0.02 | 0.07 | 0.25 |
| Profit before tax | 2.46 | 2.56 | 0.02 | 1.22 |
| Tax % | 22.76 | 23.44 | -50 | 59.84 |
| Net Profit | 1.9 | 1.95 | 0.03 | 0.48 |
| EPS in Rs | 24.24 | 3.11 | 0.04 | 0.56 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 9.6 | 6.54 | 16.03 | 25.04 | 25.47 |
| Expenses | 9.96 | 5.02 | 12.21 | 19.6 | 26.04 |
| Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.57 |
| OPM % | -3.75 | 23.24 | 23.83 | 21.73 | -2.24 |
| Other Income | 0.96 | 0.65 | 0.25 | 0.57 | 6.12 |
| Interest | 0.43 | 0.72 | 0.76 | 0.95 | 0.63 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.04 | 0.32 |
| Profit before tax | 0.16 | 1.41 | 3.25 | 5.02 | 4.6 |
| Tax % | 31.25 | 25.53 | 25.23 | 23.11 | 15.87 |
| Net Profit | 0.11 | 1.06 | 2.43 | 3.85 | 3.87 |
| EPS in Rs | 1.57 | 15.14 | 31 | 6.14 | 4.55 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.7 | 0.7 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.4 | 4.76 | 30.35 |
| Borrowings | 3.31 | 5.24 | 6.82 | 7.25 | 5.11 |
| Other Liabilities | 5.25 | 6.46 | 6.7 | 9.84 | 7.68 |
| Total Liabilities | 9.49 | 13.69 | 20.7 | 28.12 | 51.65 |
| Fixed Assets | 0.92 | 1.13 | 0.97 | 0.96 | 10.69 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8.57 | 12.56 | 19.73 | 27.16 | 40.96 |
| Total Assets | 9.49 | 13.69 | 20.7 | 28.12 | 51.65 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -1.19 | -0.32 | -3.97 | -0.03 | -10.18 |
| Cash from Investing Activity | 0 | -0.91 | -0.01 | 0.73 | -9.91 |
| Cash from Financing Activity | 1.29 | 1.21 | 3.86 | -0.51 | 21.18 |
| Net Cash Flow | 0.1 | -0.01 | -0.12 | 0.19 | 1.09 |
| Free Cash Flow | -1.19 | -0.57 | -3.98 | -0.06 | -20.24 |
| CFO/OP | 322 | -20 | -92 | 0 | 1368 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 243.33 | 480.53 | 380.71 | 357.86 | 524.07 |
| Inventory Days | 27.24 | 204.29 | 53.91 | 18.59 | 16.14 |
| Days Payable | 246.78 | 754.51 | 217.5 | 154.11 | 120.76 |
| Cash Conversion Cycle | 23.79 | -69.7 | 217.12 | 222.34 | 419.45 |
| Working Capital Days | -12.17 | 43.53 | 162.8 | 178.86 | 434.22 |
| ROCE % | — | 37.14 | 37.78 | 36.62 | 16.8 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Promoters | 50.66% | 50.66% | 50.66% |
| FIIs | 9.7% | 6.04% | 1.91% |
| DIIs | 4.08% | 0% | 0% |
| Government | 0% | 0% | 0% |
| Public | 30.95% | 37.06% | 40.53% |
| Others | 4.61% | 6.24% | 6.9% |
| No. of Shareholders | 662 | 751 | 687 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 5 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 111.05 | Sell |
| EMA (10) | 107.59 | Buy |
| SMA (20) | 101.03 | Buy |
| EMA (20) | 101.7 | Buy |
| SMA (50) | 84.26 | Buy |
| EMA (50) | 90.56 | Buy |
| SMA (100) | 80.58 | Buy |
| EMA (100) | 85.63 | Buy |
| SMA (200) | 82.81 | Buy |
| EMA (200) | 87.78 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 60.62 | Neutral |
| MACD (12,26,9) | 8.03 | Sell |
| Stochastic (14,3,3) | 60.01 | Neutral |
| ADX (14) | 40.49 | Buy |
| Williams %R (14) | -37.92 | Neutral |
| ATR (14) | 7.11 | High Volatility |
| ROC (12) | 13.48 | Buy |
| Stoch RSI (14) | 14.39 | Buy |
| UO (7,14,28) | 58.15 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-07 | [Notice Of 7Th Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b9a62fc-357f-416f-bfe4-ed9eb09c0d85.pdf) |
| 2026-09-07 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ed70f547-b49d-42ad-9c6e-81e188ca8736.pdf) |
| 2026-09-05 | [Board Meeting Outcome for Allotment Of 2410431 Equity Shares Via Preferential Allotment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=546e630c-7424-40c2-bab4-b3a98777abab.pdf) |
| 2026-09-05 | [Announcement under Regulation 30 (LODR)-Allotment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=827a942f-b6db-4e51-9bd7-618b6a7166a6.pdf) |
| 2026-09-04 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0D8792F4_36D1_42E8_8546_FA6E02F011AC_111520.pdf) |
| 2026-09-04 | [Board Meeting Outcome for Out Come Of The Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74fee938-6942-42ac-9733-75229d6cb22c.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b9e2910-712d-4866-9567-9d2ccbf8607a.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5f2872e-0563-46f5-9461-91d6c58bcdd3.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Meeting Updates](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4675fc58-9017-4128-a7c4-d2ea0e5b1df0.pdf) |
| 2026-09-04 | [Fixing 29Th September 2026 As The Date For Convening The 7Th Annual General Meeting Of The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62dc4bf3-4540-4fbd-bf1d-9fae34dc19c2.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-29 | [Audited Financial Results For The Financial Year Ended 31St March 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48104e1a-18dc-4449-ad76-8fb38c91bc69.pdf) |
| 2026-05-29 | [Audited Financial Results For The Financial Year Ended 31St March 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d1df0a11-6dbd-49c2-ad9c-67140eb47b44.pdf) |
| 2025-11-14 | [Unaudited Financial Results For The Half Year Ended 30Th September 2025 Along With A Limited Review Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=083cce11-3134-4011-a589-92074ccc9d02.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8h - Board meeting 30 Mar 2026 to consider appointing Sumit Pawar (CFO), two directors, note auditor, EGM. | [Board Meeting Intimation for Scheduled To Be Held On 30Th March, 2026 At 3:00 P.M. At The Registered Office Of The Company 8h - Board meeting 30 Mar 2026 to consider appointing Sumit Pawar (CFO), two directors, note auditor, EGM.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ac8ad3c4-7f85-4350-b4fe-65daf500856b.pdf) |
| 7 Feb - Board meeting scheduled for 07 Feb 2026 canceled; revised date to be notified. | [Cancellation of Board Meeting 7 Feb - Board meeting scheduled for 07 Feb 2026 canceled; revised date to be notified.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a51aff19-cefd-47e1-a8b1-156dc1feff9f.pdf) |
| 30 Mar - Appointed Sumit Pawar CFO; Yashvardhan Tupe and Sandip Sharma directors effective 30 Mar 2026; EGM 28 Apr 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 30 Mar - Appointed Sumit Pawar CFO; Yashvardhan Tupe and Sandip Sharma directors effective 30 Mar 2026; EGM 28 Apr 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ffe96a3a-ed29-48f1-81a8-c420e87e8517.pdf) |
| 30 Mar - Appointed Sumit Pawar as CFO; two directors added; EGM set for 28 April 2026. | [Announcement under Regulation 30 (LODR)-Meeting Updates 30 Mar - Appointed Sumit Pawar as CFO; two directors added; EGM set for 28 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f0edb6b-ee23-4118-9c00-f0413a8b92a9.pdf) |
| 30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/71a187a6-7b91-44ea-8417-7d39d00bfe73.pdf) |
| 30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Asston Pharmaceuticals confirms it is not a large corporate; outstanding borrowing was Rs 5.04 crore as of 31 Mar 2024.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/71a187a6-7b91-44ea-8417-7d39d00bfe73.pdf) |
| 29 Jan - M/s. Doshi Doshi & Co resigned as statutory auditor effective January 28, 2026; no concerns noted. | [Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 29 Jan - M/s. Doshi Doshi & Co resigned as statutory auditor effective January 28, 2026; no concerns noted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1089c796-a841-4c5c-9461-4f620bb295ca.pdf) |
| 28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors. | [Shareholder Meeting / Postal Ballot-Outcome of EGM 28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6fe29210-6c4a-4e47-baec-6c1d21ff4b3d.pdf) |
| 28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors. | [Shareholder Meeting / Postal Ballot-Outcome of EGM 28 Apr - EGM on 28 April 2026 approved statutory auditor appointment and regularized three directors.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/6fe29210-6c4a-4e47-baec-6c1d21ff4b3d.pdf) |
| 26 Mar - Trading window closed from 01 April 2026 until 48 hours after audited results for year ended 31 March 2026. | [Closure of Trading Window 26 Mar - Trading window closed from 01 April 2026 until 48 hours after audited results for year ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5dc7bc27-6eaf-4413-8a06-5f79197843f0.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0193e31b-715c-4f27-b437-147ffefe2ca7.pdf) |
| from bse | [Financial Year 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/501061/5010610316.pdf) |
| from bse | [Financial Year 2015 from bse](https://www.bseindia.com/bseplus/AnnualReport/501061/5010610315.pdf) |
| from bse | [Financial Year 2014 from bse](https://www.bseindia.com/bseplus/AnnualReport/501061/5010610314.pdf) |
| from bse | [Financial Year 2013 from bse](https://www.bseindia.com/bseplus/AnnualReport/501061/5010610313.pdf) |
| from bse | [Financial Year 2012 from bse](https://www.bseindia.com/bseplus/AnnualReport/501061/5010610312.pdf) |
| from bse | [Financial Year 2011 from bse](https://www.bseindia.com/bseplus/AnnualReport/501061/5010610311.pdf) |
| from bse | [Financial Year 2010 from bse](https://www.bseindia.com/bseplus/AnnualReport/501061/5010610310.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:54.526Z.